{
    "clinical_study": {
        "@rank": "53543", 
        "acronym": "GOOD-SHEPARD", 
        "arm_group": {
            "arm_group_label": "Immunoglobulin Therapy", 
            "description": "Immunoglobulin Therapy"
        }, 
        "brief_summary": {
            "textblock": "Primary:\n\n      \u2022 Demonstrate the utility of a new electronic data capture (EDC) system (CareExchange\u2122)\n      using infusion nurse measured physical, quality of life (QOL), respiratory, and disability\n      assessments.\n\n      Secondary:\n\n        -  Change in Intravenous Immunoglobulin (IVIg) dose effects measured outcomes.\n\n        -  Change in IVIg dose and timing effects measured outcomes.\n\n        -  Change in patient status is reflected in measured outcomes.\n\n        -  Assess the value to physicians from infusion nurse collected outcomes data.\n\n        -  Identify types of patients by response to IVIg therapy (i.e. natural or poor\n           responders).\n\n        -  Change in response rate to IVIg therapy by disease state and demographics."
        }, 
        "brief_title": "Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Evidence, Patient Care And Research Data (GOOD-SHEPARD)", 
        "completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Intravenous Immunoglobulin (IVIg) Therapy in a Home Infusion Setting", 
        "detailed_description": {
            "textblock": "This is a prospective, observational evaluation of immunoglobulin (Ig) therapy in consenting\n      adult and assenting pediatric subjects who receive infusion services from AxelaCare Health\n      Solutions, LLC.  Subjects meeting all inclusion criteria who have provided informed\n      consent/assent for trial participation will have validated, physician-prescribed, and\n      standard-of-care outcome measures recorded during normal home infusion visits.  Collected\n      data will be de-identified and aggregated into cohorts of like diagnosis for trend analysis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age at enrollment \u2265 7\n\n          -  Sign informed consent/assented to participation\n\n          -  Ability to read and write English\n\n          -  Understanding of study procedures and ability to comply with study procedures for the\n             entire length of the study\n\n          -  Receiving IVIg under the discretion of the patient's treating physician in accordance\n             with standard treatment practices\n\n          -  Have been on or is between doses of IVIg under the discretion of the patient's\n             treating physician in accordance with standard treatment practices\n\n          -  Being considered to be prescribed IVIg under the discretion of the patient's treating\n             physician in accordance with standard treatment practices\n\n          -  Determined to be clinically eligible for infusion services by AxelaCare Health\n             Solutions, LLC. in collaboration with the patient's prescribing physician\n\n        Exclusion Criteria:\n\n          -  Children (age \u2264 6 years)\n\n          -  Prisoners, and other wards of the state"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "7 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Any patient who is aged 7 years or greater at time of enrollment; who is on Ig therapy,\n        have been on or is between doses of Ig therapy, or is being considered to be prescribed Ig\n        therapy; provides informed consent for participation; and who has been determined to be\n        clinically eligible for infusion services by AxelaCare Health Solutions, LLC, in\n        collaboration with the patient's prescribing physician. Subjects will be recruited from\n        the practices of participating physicians."
            }
        }, 
        "enrollment": {
            "#text": "1500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01774331", 
            "org_study_id": "AHS1-12-001"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gamma-Globulins", 
                "Immunoglobulins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 10, 2013", 
        "location": {
            "contact": {
                "last_name": "NA"
            }, 
            "facility": {
                "address": {
                    "city": "Lenexa", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66219"
                }, 
                "name": "AxelaCare Health Solutions, LLC"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Evidence, Patient Care And Research Data (GOOD-SHEPARD)", 
        "other_outcome": [
            {
                "measure": "Demonstration of response rate for those receiving IVIg.", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "measure": "Exhibit differences in response rate of IVIg therapy across  disease states and demographics.", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "measure": "Demonstration of measured variables within patients who receive IVIg.", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }
        ], 
        "overall_contact": {
            "email": "twalton@axelacare.com", 
            "last_name": "Timothy Walton, MHS, CCRP", 
            "phone": "877-342-9352"
        }, 
        "overall_contact_backup": {
            "email": "cturk@axelacare.com", 
            "last_name": "Callie Turk, RN, MSN", 
            "phone": "877-342-9352"
        }, 
        "overall_official": {
            "affiliation": "Northwestern University", 
            "last_name": "Jeffrey A. Allen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Analysis of collected data captured in CareExchange\u2122 will demonstrate the ability to show and track changes in outcome data.", 
            "safety_issue": "No", 
            "time_frame": "5 Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01774331"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Physician feedback will demonstrate that having real-time access to patient data captured during a home infusion will assist in the management of the patient's disease.", 
            "safety_issue": "No", 
            "time_frame": "5 Years"
        }, 
        "source": "AxelaCare Health Solutions, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AxelaCare Health Solutions, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}